The clonal evolution of tumor cell populations

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
2. Nowell PC. The clonal evolution of tumor cell populations. Science
1976;194:23–28.
3. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol
2006;1:331–348.
4. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different
disease. Nat Rev Cancer 2007;7:778–790.
5. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer
2008;123:1–7.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med
2008;359:1367–1380.
7. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of
tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.
Nat Genet 2008;40:616–622.
8. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for
lung cancer maps to nicotinic acetylcholine receptor subunit genes on
15q25. Nature 2008;452:633–637.
9. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine
dependence, lung cancer and peripheral arterial disease. Nature
2008;452:638–642.
10. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular
pathogenesis of human lung cancer. Biochim Biophys Acta
1998;1378:F21–F59.
11. Albanell J, Lonardo F, Rusch V, et al. High telomerase activity in primary
lung cancers: association with increased cell proliferation rates and
advanced pathologic stage. J Natl Cancer Inst 1997;89:1609–1615.
12. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell
and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895–902.
13. Frias C, Garcia-Aranda C, De Juan C, et al. Telomere shortening is
associated with poor prognosis and telomerase activity correlates with
DNA repair impairment in non-small cell lung cancer. Lung Cancer
2008;60:416–425.
14. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1
as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008;
27(25):3635–3640.
15. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in
lung adenocarcinoma. Nature 2007;450:893–898.
16. Merlino GT, Xu YH, Ishii S, et al. Amplification and enhanced expression
of the epidermal growth factor receptor gene in A431 human
carcinoma cells. Science 1984;224:417–419.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell
lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
18. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A
2004;101:13306–13311.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science
2004;304:1497–1500.
20. Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis
of non-small cell lung cancer using array comparative genomic hybridization:
implications of the phosphatidylinositol 3-kinase pathway.
Cancer Res 2002;62:3636–3640.
21. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with
properties of the gene that predisposes to retinoblastoma and osteosarcoma.
Nature 1986;323:643–646.
22. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin- dependent
kinase-4 inhibitor gene in multiple human cancers. Nature 1994;
368:753–756.
23. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate
tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is
mutated in multiple advanced cancers. Nat Genet 1997;15:356–362.
24. Fong, KM, Sekido, Y, Minna, JD. Molecular pathogenesis of lung cancer.
J Thorac Cardiovasc Surg 1999;118:1136–1152.
25. Fong KM, Kida Y, Zimmerman PV, et al. Loss of heterozygosity frequently
affects chromosome 17q in non-small cell lung cancer. Cancer
Res 1995;55:4268–4272.
26. Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of
cancer. Science 2002;297:63–64.
27. Normanno N, Bianco C, Strizzi L, et al. The ErbB receptors and their
ligands in cancer: an overview. Curr Drug Targets 2005;6:243–257.
28. Arteaga CL. Overview of epidermal growth factor receptor biology and its
role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3–9.
29. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression
of the epidermal growth factor receptor and its ligands in primary
non-small cell lung cancers and adjacent benign lung. Cancer Res
1993;53:2379–2385.
30. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor
family in lung cancer and premalignancy. Semin Oncol 2002;29:3–14.
31. Herbst, RS. Review of epidermal growth factor receptor biology. Int J
Radiat Oncol Biol Phys 2004;59:21–26.
32. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal
growth factor receptor levels and other prognostic parameters in nonsmall
cell lung cancer. Eur J Cancer 1996;32A:2070–2074.
33. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing
EGFR mutations in lung cancer activate anti-apoptotic pathways.
Science 2004;305:1163–1167.
34. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas
to gefitinib or erlotinib is associated with a second mutation
in the EGFR kinase domain. PLoS Med 2005;2:E73.
35. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and
resistance of non-small-cell lung cancer to gefitinib. N Engl J Med
2005;352:786–792.
36. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or
without T790M mutations in EGFR mutant lung tumors with acquired
resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A
2007;104:20932–20937.
37. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary
T790M mutations in epidermal growth factor receptor-mutant
lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clin Cancer Res 2006;12:6494–6501.
38. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth
factor receptor gene mutation in patients with non-small cell
lung cancer and acquired resistance to gefitinib. Clin Cancer Res
2006;12:5764–5769.
39. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci U S A 2005;102:7665–7670.
40. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical implications.
Cancer Res 2004;64:8919–8923.
41. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification
leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science 2007;316:1039–1043.
42. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in
survival of patients with lung cancer: a systematic review of the literature
with meta-analysis. Br J Cancer 2005;92:131–139.
43. Shields JM, Pruitt K, McFall A, et al. Understanding Ras: ‘it ain’t over
’til it’s over’. Trends Cell Biol 2000;10:147–154.
44. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation
in human lung cancer. Cancer Res 1992;52:S2665–S2669 .
45. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary
resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med
2005;2:E17.
46. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal
growth factor receptor and in KRAS are predictive and prognostic
indicators in patients with non-small-cell lung cancer treated with
chemotherapy alone and in combination with erlotinib. J Clin Oncol
2005;23:5900–5909.
47. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive
spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clin Cancer Res 2008;14:5731–5734.
48. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge
on activation of the mitogen-activated protein kinase pathway in
lung cancer mouse models. Cancer Res 2007;67:4933–4939.
49. Adhikary S, Eilers, M. Transcriptional regulation and transformation
by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635–645.
50. Nau MM, Brooks BJ Jr, Carney DN, et al. Human small-cell lung cancers
show amplification and expression of the N-myc gene. Proc Natl
Acad Sci U S A 1986;83:1092–1096.
51. Broers JL, Viallet J, Jensen SM, et al. Expression of c-myc in progenitor
cells of the bronchopulmonary epithelium and in a large number of
non-small cell lung cancers. Am J Respir Cell Mol Biol 1993;9:33–43.
52. West KA, Linnoila IR, Belinsky SA, et al. Tobacco carcinogen-induced
cellular transformation increases activation of the phosphatidylinositol
3’-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004;64:446–
451.
53. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway
in human cancer. Nat Rev Cancer 2002;2:489–501.
54. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in
Japanese lung cancer patients. Lung Cancer 2006;54:209–215.
55. Garnis C, Lockwood WW, Vucic E, et al. High resolution analysis of
non-small cell lung cancer cell lines by whole genome tiling path array
CGH. Int J Cancer 2006;118:1556–1564.
56. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations
and copy number gains in human lung cancers. Cancer Res 2008;
68:6913–6921.
57. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer.
Cancer Cell 2007;12:9–22.
58. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1,
dephosphorylates the lipid second messenger, phosphatidylinositol
3,4,5-trisphosphate. J Biol Chem 1998;273:13375–13378.
59. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small
cell lung cancer could be related to promoter methylation. Clin Cancer
Res 2002;8:1178–1184.
60. Marsit CJ, Zheng S, Aldape K, et al. PTEN expression in non-smallcell
lung cancer: evaluating its relation to tumor characteristics, allelic
loss, and epigenetic alteration. Hum Pathol 2005;36:768–776.
61. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification
of developmental transcription factor genes in lung cancer.
Proc Natl Acad Sci U S A 2007;104:16663–16668.
62. Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol
1997;29:1471–1473.
63. Ikeda K, Clark JC, Shaw-White JR, et al. Gene structure and expression
of human thyroid transcription factor-1 in respiratory epithelial
cells. J Biol Chem 1995;270:8108–8114.
64. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the
androgen receptor gene and progression of human prostate cancer. Nat
Genet 1995;9:401–406.
65. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic
analyses identify MITF as a lineage survival oncogene amplified in
malignant melanoma. Nature 2005;436:117–122.
66. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene
amplification is frequent in breast cancer. Nat Genet 2007;39:655–660.
67. Garraway LA, Sellers WR. Lineage dependency and lineage-survival
oncogenes in human cancer. Nat Rev Cancer 2006;6:593–602.
68. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature
2007;448:561–566.
69. Meyerson M. Cancer: broken genes in solid tumours. Nature
2007;448:545–546.
70. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked
to histological characteristics in a subset of lung cancers. J Thorac Oncol
2008;3:13–17.
71. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion
genes in lung cancer. Cancer Sci 2008;99:2349–2355.
72. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene
and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res
2008;14:4275–4283.
73. Knudson AG, Jr. The ninth Gordon Hamilton-Fairley memorial
lecture. Hereditary cancers: clues to mechanisms of carcinogenesis. Br J
Cancer 1989;59:661–666.
74. Breuer RH, Postmus PE, Smit EF. Molecular pathology of non-small-cell
lung cancer. Respiration 2005;72:313–330.
75. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic
abnormalities in lung cancer. Science 1989;246:491–494.
76. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in
human cancers. Science 1991;253:49–53.
77. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in
the p53 tumor suppressor gene: clues to cancer etiology and molecular
pathogenesis. Cancer Res 1994;54:4855–4878.
78. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification
and expression in non-small-cell lung cancer: immunohistochemical
expression of its protein is a favourable prognostic marker in patients
without p53 protein accumulation. Br J Cancer 1997;75:1302–1308.
79. Gazzeri S, Della Valle V, Chaussade L, et al. The human p19ARF protein
encoded by the beta transcript of the p16INK4a gene is frequently
lost in small cell lung cancer. Cancer Res 1998;58:3926–3931.
80. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/
p16alpha and p19ARF/p16beta is frequently altered in non-small
cell lung cancer and correlates with p53 overexpression. Oncogene
1998;17:2779–2785.
81. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function
leads to tumour regression in vivo. Nature 2007;445:661–665.
82. Ohtani N, Yamakoshi K, Takahashi A, et al. The p16INK4a-RB pathway:
molecular link between cellular senescence and tumor suppression.
J Med Invest 2004;51:146–153.
83. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma
susceptibility gene in non-small-cell lung cancer. The Lung
Cancer Study Group. Oncogene 1993;8:1913–1919.
84. Merlo A, Gabrielson E, Askin F, et al. Frequent loss of chromosome
9 in human primary non-small cell lung cancer. Cancer Res 1994;54:
640–642.
85. Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb,
p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their
clinical significance. J Pathol 1999;188:351–360.
86. Sato M, Takahashi K, Nagayama K, et al. Identification of chromosome
arm 9p as the most frequent target of homozygous deletions in
lung cancer. Genes Chromosomes Cancer 2005;44:405–414.
87. Esteller M. Cancer epigenetics: DNA methylation and chromatin
alterations in human cancer. Adv Exp Med Biol 2003;532:39–49.
88. Kotake Y, Cao R, Viatour P, et al. pRB family proteins are required
for H3K27 trimethylation and Polycomb repression complexes binding
to and silencing p16INK4alpha tumor suppressor gene. Genes Dev
2007;21:49–54.
89. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome
3p allelotyping of human lung cancer and preneoplastic/
preinvasive bronchial epithelium reveals multiple, discontinuous sites
of 3p allele loss and three regions of frequent breakpoints. Cancer Res
2000;60:1949–1960.
90. Ito M, Ito G, Kondo M, et al. Frequent inactivation of RASSF1A, BLU,
and SEMA3B on 3p21.3 by promoter hypermethylation and allele
loss in non-small cell lung cancer. Cancer Lett 2005;225:131–139.
91. Kuroki T, Trapasso F, Yendamuri S, et al. Allelic loss on chromosome
3p21.3 and promoter hypermethylation of semaphorin 3B in nonsmall
cell lung cancer. Cancer Res 2003;63:3352–3355.
92. Feng Q, Hawes SE, Stern JE, et al. DNA methylation in tumor and
matched normal tissues from non-small cell lung cancer patients.
Cancer Epidemiol Biomarkers Prev 2008;17:645–654.
93. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell
lung carcinoma. Semin Oncol 2001;28:3–13.
94. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation
in lung cancer: biological and clinical implications. Oncologist
2002;7:451–457.
95. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer
cells suppresses tumorigenicity. Proc Natl Acad Sci U S A 1997;
94:13771–13776.
96. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association
domain family 1 tumor suppressor gene in human cancers. Cancer Res
2005;65:3497–508.
97. Ji L, Roth JA. Tumor suppressor FUS1 signaling pathway. J Thorac
Oncol 2008;3:327–330.
98. Deng WG, Kawashima H, Wu G, et al. Synergistic tumor suppression
by coexpression of FUS1 and p53 is associated with down-regulation
of murine double minute-2 and activation of the apoptotic proteaseactivating
factor 1-dependent apoptotic pathway in human non-small
cell lung cancer cells. Cancer Res 2007;67:709–717.
99. Tomizawa Y, Sekido Y, Kondo M, et al. Inhibition of lung cancer cell
growth and induction of apoptosis after reexpression of 3p21.3 candidate
tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 2001;
98:13954–13959.
100. Ochi K, Mori T, Toyama Y, et al. Identification of semaphorin3B as a
direct target of p53. Neoplasia 2002;4:82–87.
101. Castro-Rivera E, Ran S, Brekken RA, et al. Semaphorin 3B inhibits
the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1
in lung and breast cancer cells. Cancer Res 2008;68:8295–8303.
102. Brambilla E, Constantin B, Drabkin H, et al. Semaphorin SEMA3F
localization in malignant human lung and cell lines: a suggested role in
cell adhesion and cell migration. Am J Pathol 2000;156:939–950.
103. Kessler O, Shraga-Heled N, Lange T, et al. Semaphorin-3F is an inhibitor
of tumor angiogenesis. Cancer Res 2004;64:1008–1015.
104. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of
LKB1 genetic alterations in lung cancers. Oncogene 2007;26:5911–5918.
105. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways.
Annu Rev Biochem 2006;75:137–163.
106. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor
negatively regulates mTOR signaling. Cancer Cell 2004;6:91–99.
107. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev
2002;16:6–21.
108. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA
methylation, chromatin formation and gene expression in cancer. Hum
Mol Genet 2001;10:687–692.
109. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA
hypermethylation and hypomethylation in lung cancer. Proc Natl Acad
Sci U S A 2008;105:252–257.
110. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter
methylation in lung cancer identifies novel methylation markers
for multiple malignancies. PLoS Med 2006;3:E486.
111. Zhong S, Fields CR, Su N, et al. Pharmacologic inhibition of epigenetic
modifications, coupled with gene expression profiling, reveals novel
targets of aberrant DNA methylation and histone deacetylation in lung
cancer. Oncogene 2007;26:2621–2634.
112. Brena RM, Morrison C, Liyanarachchi S, et al. Aberrant DNA methylation
of OLIG1, a novel prognostic factor in non-small cell lung
cancer. PLoS Med 2007;4:E108.
113. Metzler M, Wilda M, Busch K, et al. High expression of precursor
microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes
Chromosomes Cancer 2004;39:167–169.
114. Michael, MZ, O’Connor SM, van Holst Pellekaan NG, et al. Reduced
accumulation of specific microRNAs in colorectal neoplasia. Mol
Cancer Res 2003;1:882–891.
115. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and downregulation
of micro-RNA genes miR15 and miR16 at 13q14 in chronic
lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524–15529.
116. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005;
102:3627–3632.
117. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a
potential human oncogene. Nature 2005;435:828–833.
118. Ota A, Tagawa H, Karnan S, et al. Identification and characterization
of a novel gene, C13orf25, as a target for 13q31-q32 amplification in
malignant lymphoma. Cancer Res 2004;64:3087–3095.
119. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates
miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
Cell 2006;124:1169–1181.
120. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of
the let-7 microRNAs in human lung cancers in association with shortened
postoperative survival. Cancer Res 2004;64:3753–3756.
121. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA
cluster, miR-17-92, is overexpressed in human lung cancers and enhances
cell proliferation. Cancer Res 2005;65:9628–9632.
122. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes
are frequently located at fragile sites and genomic regions involved in
cancers. Proc Natl Acad Sci U S A 2004;101:2999–3004.
123. Sevignani C, Calin GA, Nnadi SC, et al. MicroRNA genes are frequently
located near mouse cancer susceptibility loci. Proc Natl Acad
Sci U S A 2007;104:8017–8022.
124. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival
and relapse in lung cancer. Cancer Cell 2008;13:48–57.
125. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular
profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;
9:189–198.
126. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts
aberrant methylation in lung cancer by targeting DNA methyltransferases
3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805–15810.
127. Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion
in non-small cell lung carcinoma cell lines. Biochem Biophys Res
Commun 2008;373:607–612.
128. Nasser MW, Datta J, Nuovo G, et al. Downregulation of microRNA-1
(miR-1) in lung cancer: suppression of tumorigenic property of lung
cancer cells and their sensitization to doxorubicin induced apoptosis
bymiR-1. J Biol Chem 2008;283(48):33394–33405.
129. Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA
in lung cancer: correlation with clinical response and survival to gefitinib
and EGFR expression in cell lines. Ann Oncol 2008;19:1053–1059.
130. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in nonsmall
cell lung cancer by quantitative real-time RT-PCR. Clin Chem
2008;54(10):1696–1704.
131. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures
of TRAIL resistance in human non-small cell lung cancer. Oncogene
2008;27:3845–3855.
132. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature
of human solid tumors defines cancer gene targets. Proc Natl Acad Sci
U S A 2006;103:2257–2261.
133. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the
let-7 microRNA family. Cell 2005;120:635–647.
134. Lee YS, Dutta, A. The tumor suppressor microRNA let-7 represses the
HMGA2 oncogene. Genes Dev 2007;21:1025–1030.
135. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between
let-7 and Hmga2 enhances oncogenic transformation. Science 2007;
315:1576–1579.
136. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA
represses cell proliferation pathways in human cells. Cancer
Res 2007;67:7713–7722.
137. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA
reduces tumor growth in mouse models of lung cancer. Cell Cycle
2008;7:759–764.
138. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell
lung tumor development by the let-7 microRNA family. Proc Natl Acad
Sci U S A 2008;105:3903–3908.
139. Daniel VC, Peacock CD, Watkins DN. Developmental signalling
pathways in lung cancer. Respirology 2006;11:234–240.
140. Olsen CL, Hsu PP, Glienke J, et al. Hedgehog-interacting protein is
highly expressed in endothelial cells but down-regulated during angiogenesis
and in several human tumors. BMC Cancer 2004;4:43.
141. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic
target in cancer: a new approach to the development of cell fate modifying
agents. Oncogene 2003;22:6598–6608.
142. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer.
Nat Rev Drug Discov 2006;5:1026–1033.
143. Riobo NA, Lu K, Emerson CP Jr. Hedgehog signal transduction: signal
integration and cross talk in development and cancer. Cell Cycle
2006;5:1612–1615.
144. Lauth M, Toftgard R. Non-canonical activation of GLI transcription
factors: implications for targeted anti-cancer therapy. Cell Cycle
2007;6:2458–2463.
145. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling
within airway epithelial progenitors and in small-cell lung cancer.
Nature 2003;422:313–317.
146. Yuan Z, Goetz JA, Singh S, et al. Frequent requirement of hedgehog signaling
in non-small cell lung carcinoma. Oncogene 2007;26:1046–1055.
147. Dang TP, Eichenberger S, Gonzalez A, et al. Constitutive activation
of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic
mice. Oncogene 2003;22:1988–1997.
148. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development
and breast cancer. Semin Cancer Biol 2004;14:341–347.
149. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and
Notch-2 with clinical outcome and tumour clinicopathological parameters
in human breast cancer. Int J Mol Med 2004;14:779–786.
150. Hainaud P, Contreres JO, Villemain A, et al. The role of the vascular
endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade
in tumor vessel remodeling and endothelial cell functions. Cancer
Res 2006;66:8501–8510.
151. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features
in mammospheres from human ductal breast carcinoma and normal
mammary gland. J Clin Invest 2007;117:3988–4002.
152. Haruki N, Kawaguchi KS, Eichenberger S, et al. Dominant-negative
Notch3 receptor inhibits mitogen-activated protein kinase pathway and
the growth of human lung cancers. Cancer Res 2005;65:3555–3561.
153. Ishihara K, Hirano T. Molecular basis of the cell specificity of cytokine
action. Biochim Biophys Acta 2002;1592:281–296.
154. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor
in cancer: implications for Translational Therapeutics. Cancer
2007;110:1911–1928.
155. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain
mediate STAT3 activation via IL-6 production in human lung
adenocarcinomas. J Clin Invest 2007;117:3846–3856.
156. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1
induces apoptosis in human cancer cells. Neoplasia 2004;6:7–14.
157. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling
induces programmed cell death in non-small-cell lung cancer cells.
Oncogene 2004;23:6170–6174.
158. Winn RA, Van Scoyk M, Hammond M, et al. Antitumorigenic effect
of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated
through ERK-5-dependent activation of peroxisome proliferatoractivated
receptor gamma. J Biol Chem 2006;281:26943–26950.
159. Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted
frizzled related protein 1 (SFRP 1) by promoter hypermethylation in
non-small-cell lung cancer. Oncogene 2005;24:6323–6327.
160. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by
promoter hypermethylation in human lung cancer. Cancer Res 2004;
64:4717–4720.
161. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non
small cell lung cancer: evidence of dishevelled overexpression. Oncogene
2003;22:7218–7221.
162. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the
Wnt pathway, is down-regulated in prostate, breast, lung, and bladder
cancer. J Pathol 2003;201:204–212.
163. Syrjanen KJ. Condylomatous changes in neoplastic bronchial epithelium.
Report of a case. Respiration 1979;38:299–304.
164. Klein F, Kotb WF, Petersen I. Incidence of human papilloma virus in
lung cancer. Lung Cancer 2008.
165. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict
survival of patients with lung adenocarcinoma. Nat Med 2002;
8:816–824.
166. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human
cancers as a guide to targeted therapies. Nature 2006;439:353–357.
167. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the
use of chemotherapeutics. Nat Med 2006;12:1294–1300.
168. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based
survival prediction in lung adenocarcinoma: a multi-site, blinded validation
study. Nat Med 2008;14:822–827.
169. Anguiano A, Nevins JR, Potti A. Toward the individualization of lung
cancer therapy. Cancer 2008;113:1760–1767.
170. Xie Y, Minna JD. Predicting the future for people with lung cancer.
Nat Med 2008;14:812–813.
171. Tonon G, Wong KK, Maulik G, et al. High-resolution genomic
profiles of human lung cancer. Proc Natl Acad Sci U S A 2005;
102:9625–9630.
172. Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and
chromosome amplifications in human lung carcinomas revealed
by single nucleotide polymorphism array analysis. Cancer Res 2005;
65:5561–5570.
173. Shibata T, Uryu S, Kokubu A, et al. Genetic classification of lung adenocarcinoma
based on array-based comparative genomic hybridization
analysis: its association with clinicopathologic features. Clin Cancer Res
2005;11:6177–6185.
174. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways
in lung adenocarcinoma. Nature 2008;455:1069–1075.
175. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene
transcripts in small cell lung cancer. Cancer Res 1991;
51:2416–2419.
176. Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status
of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res
2004;10:4101–4108.
177. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth
factor receptor signaling pathway in lung cancers. Int J Cancer 2006;
118:257–262.
178. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of
BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008;
32:1317–1321.
179. Hirsch FR, Varella-Garcia M, Bunn PA, Jr, et al. Epidermal growth
factor receptor in non-small-cell lung carcinomas: correlation between
gene copy number and protein expression and impact on prognosis.
J Clin Oncol 2003;21:3798–3807.
180. Nakamura H, Saji H, Ogata A, et al. Correlation between encoded protein
overexpression and copy number of the HER2 gene with survival
in non-small cell lung cancer. Int J Cancer 2003;103:61–66.
181. Hirashima N, Takahashi W, Yoshii S, et al. Protein overexpression
and gene amplification of c-erb B-2 in pulmonary carcinomas: a
comparative immunohistochemical and fluorescence in situ hybridization
study. Mod Pathol 2001;14:556–562.
182. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor
receptor mutations in small cell lung cancer. Clin Cancer Res 2008;
14:6092–6096.
183. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small
cell lung cancer. Clin Cancer Res 2006;12:4377s–4383s.
184. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation
of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma
of the lung. N Engl J Med 1987;317:929–935.
185. De Biasi F, Del Sal G, Hand PH. Evidence of enhancement of the ras
oncogene protein product (p21) in a spectrum of human tumors. Int J
Cancer 1989;43:431–435.
186. Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in
lung cancer. Cancer Lett 2009;273(1):1–14.
187. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of
the PIK3CA gene in human cancers. Science 2004;304:554.
188. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated
in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;
24:1477–1480.
189. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase
gene family in human lung cancer. Cancer Res 2005;65:7591–7595.
190. Micke P, Hengstler JG, Ros R, et al. c-erbB-2 expression in smallcell
lung cancer is associated with poor prognosis. Int J Cancer 2001;
92:474–479.
191. Potti A, Willardson J, Forseen C, et al. Predictive role of HER-2/neu overexpression
and clinical features at initial presentation in patients with extensive
stage small cell lung carcinoma. Lung Cancer 2002;36:257–261.
192. Dworakowska D, Jassem E, Jassem J, et al. MDM2 gene amplification:
a new independent factor of adverse prognosis in non-small cell lung
cancer (NSCLC). Lung Cancer 2004;43:285–295.
193. Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy
number and primary resistance to gefitinib therapy in non-small-cell
lung cancer patients. Ann Oncol 2009;20(2):298–304.
194. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number
in non-small cell lung cancer: molecular analysis in a targeted tyrosine
kinase inhibitor naive cohort. J Thorac Oncol 2008;3:331–339.
195. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol
1993;20:105–127.
196. Johnson BE, Russell E, Simmons AM, et al. MYC family DNA amplification
in 126 tumor cell lines from patients with small cell lung
cancer. J Cell Biochem Suppl 1996;24:210–217.
197. Ibson JM, Waters JJ, Twentyman PR, et al. Oncogene amplification
and chromosomal abnormalities in small cell lung cancer. J Cell
Biochem 1987;33:267–288.
198. Shiraishi M, Noguchi M, Shimosato Y, et al. Amplification of protooncogenes
in surgical specimens of human lung carcinomas. Cancer Res
1989;49:6474–6479.
199. Miller CT, Chen G, Gharib TG, et al. Increased C-CRK protooncogene
expression is associated with an aggressive phenotype in lung
adenocarcinomas. Oncogene 2003;22:7950–7957.
200. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung
carcinoma. N Engl J Med 1993;329:690–694.
201. Kaiser U, Schilli M, Haag U, et al. Expression of bcl-2—protein in
small cell lung cancer. Lung Cancer 1996;15:31–40.
202. Reissmann PT, Koga H, Figlin RA, et al. Amplification and overexpression
of the cyclin D1 and epidermal growth factor receptor genes in
non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res
Clin Oncol 1999;125:61–70.
203. Eren B, Sar M, Oz B, et al. MMP-2, TIMP-2 and CD44v6 expression
in non-small-cell lung carcinomas. Ann Acad Med Singapore 2008;
37:32–39.
204. Junker K, Wiethege T, Muller KM. Pathology of small-cell lung cancer.
J Cancer Res Clin Oncol 2000;126:361–368.
205. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression
in small cell lung cancer: prognostic and therapeutic implications. Clin
Cancer Res 2003;9:188–194.
206. Cook RM, Miller YE, Bunn PA, Jr. Small cell lung cancer: etiology,
biology, clinical features, staging, and treatment. Curr Probl Cancer
1993;17:69–141.
207. Araki K, Ishii G, Yokose T, et al. Frequent overexpression of the ckit
protein in large cell neuroendocrine carcinoma of the lung. Lung
Cancer 2003;40:173–180.
208. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the protooncogenes
c-met and c-kit and their ligands, hepatocyte growth factor/
scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br
J Cancer 1993;67:37–46.
209. Plummer H 3rd, Catlett J, Leftwich J, et al. c-myc expression correlates
with suppression of c-kit protooncogene expression in small cell lung
cancer cell lines. Cancer Res 1993;53:4337–4342.
210. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem
cell factor and the c-kit genes in small-cell lung cancer. Oncogene
1991;6:2291–2296.
211. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu
gene-encoded protein (P185neu) in human non-small cell carcinomas
of the lung. Cancer Res 1990;50:421–425.
212. Schneider PM, Hung MC, Chiocca SM, et al. Differential expression
of the c-erbB-2 gene in human small cell and non-small cell lung
cancer. Cancer Res 1989;49:4968–4971.
213. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required
for constitutive stat 3 activation in malignant human lung epithelial
cells. Int J Cancer 1999;83:564–570.
214. Rygaard K, Vindelov LL, Spang-Thomsen M. Expression of myc family
oncoproteins in small-cell lung-cancer cell lines and xenografts. Int
J Cancer 1993;54:144–152.
215. Takahashi T, Obata Y, Sekido Y, et al. Expression and amplification of
myc gene family in small cell lung cancer and its relation to biological
characteristics. Cancer Res 1989;49:2683–2688.
216. Spencer CA, Groudine M. Control of c-myc regulation in normal and
neoplastic cells. Adv Cancer Res 1991;56:1–48.
217. Zhang P, Gao WY, Turner S, et al. Gleevec (STI-571) inhibits lung
cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Mol Cancer 2003;2:1.
218. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 2007;
131:1190–1203.
219. Johnson FM, Krug LM, Tran HT, et al. Phase I studies of imatinib
mesylate combined with cisplatin and irinotecan in patients with small
cell lung carcinoma. Cancer 2006;106:366–374.
220. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and
the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and
Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol
2005;23:8774–8785.
221. Carbone DP, Mitsudomi T, Chiba I, et al. p53 immunostaining positivity
is associated with reduced survival and is imperfectly correlated
with gene mutations in resected non-small cell lung cancer. A preliminary
report of LCSG 871. Chest 1994;106:S377–S381.
222. Wistuba II, Berry J, Behrens C, et al. Molecular changes in the bronchial
epithelium of patients with small cell lung cancer. Clin Cancer Res
2000;6:2604–2610.
223. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are
frequent in primary, resected non-small cell lung cancer. Lung Cancer
Study Group. Oncogene 1990;5:1603–1610.
224. Shimizu E, Zhao M, Shinohara A, et al. Differential expressions of
cyclin A and the retinoblastoma gene product in histological subtypes
of lung cancer cell lines. J Cancer Res Clin Oncol 1997;123:533–538.
225. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin
Oncol 1998;16:1207–1217.
226. Hensel CH, Hsieh CL, Gazdar AF, et al. Altered structure and expression
of the human retinoblastoma susceptibility gene in small cell lung
cancer. Cancer Res 1990;50:3067–3072.
227. Girard L, Zochbauer-Muller S, Virmani AK, et al. Genome-wide
allelotyping of lung cancer identifies new regions of allelic loss, differences
between small cell lung cancer and non-small cell lung cancer,
and loci clustering. Cancer Res 2000;60:4894–4906.
228. Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates
common and distinct patterns of chromosomal loss in human lung
cancer types. Genes Chromosomes Cancer 1998;21:308–319.
229. Thiberville L, Payne P, Vielkinds J, et al. Evidence of cumulative gene
losses with progression of premalignant epithelial lesions to carcinoma
of the bronchus. Cancer Res 1995;55:5133–5139.
230. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1
in the development of non-small cell lung cancer versus small cell lung
cancer. Cancer Res 2004;64:4277–4285.
231. Mori S, Ito G, Usami N, et al. p53 apoptotic pathway molecules are
frequently and simultaneously altered in nonsmall cell lung carcinoma.
Cancer 2004;100:1673–1682.
232. Prudkin L, Behrens C, Liu DD, et al. Loss and reduction of FUS1
protein expression is a frequent phenomenon in the pathogenesis of
lung cancer. Clin Cancer Res 2008;14:41–47.
233. Safar AM, Spencer H 3rd, Su X, et al. Methylation profiling of archived
non-small cell lung cancer: a promising prognostic system. Clin Cancer
Res 2005;11:4400–4405.
234. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles
of lung tumors. Mol Cancer Ther 2001;1:61–67.
235. Shimamoto T, Ohyashiki JH, Hirano T, et al. Hypermethylation of
E-cadherin gene is frequent and independent of p16INK4A methylation
in non-small cell lung cancer: potential prognostic implication.
Oncol Rep 2004;12:389–395.
236. Jarmalaite S, Kannio A, Anttila S, et al. Aberrant p16 promoter methylation
in smokers and former smokers with nonsmall cell lung cancer.
Int J Cancer 2003;106:913–918.
237. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant
promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients. Cancer Res 1999;59:67–70.
238. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histologyspecific
methylation of CpG islands by exposure to tobacco smoke in
non-small cell lung cancer. Cancer Res 2001;61:3419–3424.
239. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the deathassociated
protein (DAP) kinase promoter and aggressiveness in stage I
non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511–1516.
240. Kim DS, Cha SI, Lee JH, et al. Aberrant DNA methylation profiles of
non-small cell lung cancers in a Korean population. Lung Cancer 2007;
58:1–6.
241. Suh YA, Lee HY, Virmani A, et al. Loss of retinoic acid receptor beta
gene expression is linked to aberrant histone H3 acetylation in lung
cancer cell lines. Cancer Res 2002;62:3945–3949.
242. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation
of RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst 2001;93:691–699.
243. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS
association domain family protein from the lung tumour suppressor
locus 3p21.3. Nat Genet 2000;25:315–319.
244. Speicher MR, Gwyn Ballard S, Ward DC. Karyotyping human chromosomes
by combinatorial multi-fluor FISH. Nat Genet 1996;12:368–375.
245. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer.
Oncogene 2002;21:6877–6883.
246. Luk C, Tsao MS, Bayani J, et al. Molecular cytogenetic analysis of nonsmall
cell lung carcinoma by spectral karyotyping and comparative
genomic hybridization. Cancer Genet Cytogenet 2001;125:87–99.
247. Petersen I, Bujard M, Petersen S, et al. Patterns of chromosomal imbalances
in adenocarcinoma and squamous cell carcinoma of the lung.
Cancer Res 1997;57:2331–2335.
248. Petersen I, Langreck H, Wolf G, et al. Small-cell lung cancer is characterized
by a high incidence of deletions on chromosomes 3p, 4q, 5q,
10q, 13q and 17p. Br J Cancer 1997;75:79–86.